Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03218787 · ClinicalTrials.gov registry record · NA
XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 2,047
- Enrollment target
NCT03218787: Completed NA study, sponsored by Abbott Medical Devices.
NCT03218787 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 2,047 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (46% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03218787, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,047 participants
- Enrollment target
Study Summary
XIENCE 90 study is a prospective, single arm, multi-center, open label trial to evaluate the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with the approved XIENCE family of coronary drug-eluting stents. The XIENCE family stent systems include commercially approved XIENCE Xpedition Everolimus Eluting Coronary Stent System (EECSS), XIENCE Alpine EECSS, XIENCE PRO\^X EECSS \[rebrand of the XIENCE Xpedition Stent System and is only available outside of the United States (OUS)\], XIENCE PRO\^A EECSS (rebrand of the XIENCE Alpine Stent System and is only available OUS) and XIENCE Sierra EECSS of coronary drug-eluting stents.
Primary Outcome
All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease should be classified as cardiac. MI (Modified ARC): Patients present any of the following clinical or imaging evidence of ischemia: * Clinical symptoms of ischemia; * ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block, development of pathological
Interventions
- DEVICE XIENCE
- DRUG DAPT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,047 participants |
| Start Date | 2017-07-19 |
| Est. Completion | 2020-09-04 |
| Phase | NA |
What the finished NCT03218787 record still lists
NCT03218787 is an interventional study that assigns participants to a tested intervention. Its 2,047 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (46% higher).
The record links to 0 conditions, and to 2 interventions - of which XIENCE is the first listed.
NCT03218787 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03218787 about?
NCT03218787 is a clinical study titled "XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.". XIENCE 90 study is a prospective, single arm, multi-center, open label trial to evaluate the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with the approved XIENCE family of coronary drug-eluting sten...
What is the current status of trial NCT03218787?
This trial is currently completed. It is a NA study. The enrollment target is 2,047 participants. The study started on 2017-07-19. Estimated completion is 2020-09-04.
What interventions are being tested in trial NCT03218787?
The interventions under investigation include: XIENCE (DEVICE), DAPT (DRUG).
Who is sponsoring clinical trial NCT03218787?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03218787's enrollment target sits among peer trials
2,047 52nd of 2000 higher than 1,949 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05688982 · 2,049 participants · NA
MOLAR: Mapping Oral Health and Local Area Resources
- NCT05050084 · 2,050 participants · Phase 3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
- NCT06833476 · 2,044 participants
TTVR STRONG Under Coverage With Evidence Development (CED) Study
- NCT05138718 · 2,041 participants
FDG an Myocardial Infarction: The PIAF Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI